{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:09:24Z","timestamp":1787843364604,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Mitomycin (MMC) has been frequently used as the compound for intravesical treatment. The relatively new pyrimidine analog gemcitabine (GEM) has exhibited anticancer effect on various solid cancers, such as the advanced bladder cancer. In this study, the GEM and MMC in treating non-muscle invasive bladder cancer (NMIBC) cases was compared through systemic review.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, the electronic databases, including Embase, PubMed, Chinese biomedicine literature database, the Cochrane Library, the National Institute for Health and Clinical Excellence, NHS Evidence, Chinese technological periodical full-text database, and Chinese periodical full-text database, were systemically reviewed from inception to October 2018. Then, the RevMan 5.0 software was applied for data analysis. Five randomized controlled trials (RCTs) involving a total of 335 patients were included.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>For MMC group, the recurrence rate in the mitomycin arm increased compared with that in GEM group (OR\u2009=\u20090.44 95% CI [0.24, 0.78]), and the difference was statistically significant between the two groups. GEM was associated with reduced incidence of chemical cystitis compared with that of MMC (OR\u2009=\u20090.23 95% CI [0.12, 0.44]). Differences in hematuria (OR\u2009=\u20090.46 95% CI [0.16, 1.31]), skin reaction (OR\u2009=\u20090.49 95% CI [0.14, 1.70]) and liver and kidney function damage (OR\u2009=\u20090.51 95% CI [0.09, 2.85]) displayed no statistical significance between the two groups.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Findings in our study demonstrate the superior efficacy of GEM over MMC in reducing the relapse rate among NMIBC patients following transurethral resection (TUR). In addition, GEM is associated with reduced local toxic effects on the bladder compared with those of MMC. However, more future studies are needed to examine GEM safety when used as the monotherapy or polytherapy for bladder patients. More RCTs with high quality are also required to validate our findings due to the limitations of the current meta-analysis.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12894-020-00610-9","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T10:04:06Z","timestamp":1594634646000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial"],"prefix":"10.1186","volume":"20","author":[{"given":"Rongxin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weipeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"610_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I, et al. Bladder Cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96\u2013108.","journal-title":"Eur Urol"},{"key":"610_CR2","first-page":"528","volume":"2011","author":"T Tanaka","year":"2011","unstructured":"Tanaka T, Miyazawa K, Tsukamoto T, Kuno T, Suzuki K. Pathobiology and chemoprevention of bladder Cancer. J Oncol. 2011;2011:528\u201353.","journal-title":"J Oncol"},{"key":"610_CR3","first-page":"29","volume":"13","author":"MJ Cabello","year":"2011","unstructured":"Cabello MJ, Grau L, Franco N, Orenes E, Alvarez M, Blanca A, Heredero O, Palacios A, Urrutia M, Fern\u00e1ndez JM, L\u00f3pez-Beltr\u00e1n A, S\u00e1nchez-Carbayo M. Multiplexed methylation profiles of tumor suppressor genes in bladder Cancer. J MolDiagn. 2011;13:29\u201340.","journal-title":"J MolDiagn"},{"key":"610_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1046\/j.1523-5394.2002.106011.x","volume":"10","author":"CL Pasbos","year":"2002","unstructured":"Pasbos CL. Bladder cancer, epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311\u201322.","journal-title":"Cancer Pract"},{"key":"610_CR5","volume-title":"GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5","author":"J Ferlay","year":"2001","unstructured":"Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5. Lyon: IARC Press; 2001."},{"key":"610_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF00686923","volume":"35","author":"Y Uekado","year":"1994","unstructured":"Uekado Y, Hirano A, Shinka T, Ohkawa T. The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guerin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report. Cancer Chemother Pharmacol. 1994;35:65\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"610_CR7","first-page":"1","volume":"1","author":"ER Ray","year":"2006","unstructured":"Ray ER, O\u2019Brien TS. Approaches to reducing recurrence in superficial bladder cancer. Eur Kidney Urol Dis. 2006;1:1\u20136.","journal-title":"Eur Kidney Urol Dis"},{"key":"610_CR8","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0022-5347(17)43644-5","volume":"138","author":"HW Herr","year":"1987","unstructured":"Herr HW, Laudone VP, Whitmore WF Jr. An overview of intravesical therapy for superficial bladder tumors. J Urol. 1987;138:1363\u20138.","journal-title":"J Urol"},{"key":"610_CR9","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.eursup.2007.01.028","volume":"6","author":"P Whelan","year":"2007","unstructured":"Whelan P. The treatment of non-muscle-invasive bladder Cancer with Intravesical chemotherapy and immunotherapy. Eur Urol Suppl. 2007;6:568\u201371.","journal-title":"Eur Urol Suppl"},{"key":"610_CR10","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","volume":"15","author":"WM Stadler","year":"1997","unstructured":"Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15:3394\u20138.","journal-title":"J Clin Oncol"},{"key":"610_CR11","first-page":"3","volume":"23","author":"W Plunkett","year":"1996","unstructured":"Plunkett W, Huang P, Searcy CE, et al. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996;23:3\u201315.","journal-title":"Semin Oncol"},{"key":"610_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00042307-200409000-00005","volume":"14","author":"FN Joudi","year":"2004","unstructured":"Joudi FN, O\u2019Donnel MA. Second-line intravesical therapy versus cystectomy for Bacile Calmette-Gue\u2019rin (BCG) failure. Curr Opin Urol. 2004;14:271\u20135.","journal-title":"Curr Opin Urol"},{"issue":"10","key":"610_CR13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1\u2013e34.","journal-title":"J Clin Epidemiol"},{"key":"610_CR14","doi-asserted-by":"publisher","unstructured":"Dong ZL, Yang KH, Liu YL, Mi DH, Wang ZP, Tian JH. Intravesical doxorubicin versus epirubicin for superficial bladder cancer. Cochrane Database Syst Rev. 2010, Issue 1. Art. No.:CD008181. https:\/\/doi.org\/10.1002\/14651858.CD008181.","DOI":"10.1002\/14651858.CD008181"},{"key":"610_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","volume":"41","author":"Oosterlinck","year":"2002","unstructured":"Oosterlinck. Guidelines on bladder cancer. Eur Urol. 2002;41:105\u201312.","journal-title":"Eur Urol"},{"key":"610_CR16","first-page":"109","volume":"22","author":"X Dong","year":"2017","unstructured":"Dong X, Song L, Zhang F. Curative effect analysis of different chemotherapeutics at intravesical instillation in the prevention of tumor recurrence after TUR-Bt. Zhejiang J Traumat Surg. 2017;22:109\u201310.","journal-title":"Zhejiang J Traumat Surg"},{"key":"610_CR17","first-page":"118","volume":"35","author":"T Lin","year":"2016","unstructured":"Lin T, Sun L. Comparison of the efficacy of different chemotherapy drugs in the prevention of postoperative recurrence in superficial bladder cancer by intravesical instillation. China Foreign Med Treat. 2016;35:118\u20139.","journal-title":"China Foreign Med Treat"},{"key":"610_CR18","first-page":"3238","volume":"29","author":"S Sun","year":"2016","unstructured":"Sun S, Liu R, Zhao H, et al. Comparison of intravesical perfusion of gemcitabine and mitomycin after non-muscle invasive bladder cancer. J Med Theory Pract. 2016;29:3238\u20139.","journal-title":"J Med Theory Pract"},{"key":"610_CR19","first-page":"1043","volume":"17","author":"Z Xiaohong","year":"2015","unstructured":"Xiaohong Z, Tan J, Wei Y, et al. Clinical effect of antineoplastic drug perfusion in preventing postoperative recurrence of superficial bladder cancer. J Chin Physician. 2015;17:1043\u20135.","journal-title":"J Chin Physician"},{"key":"610_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","volume":"28","author":"R Addeo","year":"2010","unstructured":"Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus Mitomycin in recurrent superficial bladder Cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2010;28:543\u20138.","journal-title":"J Clin Oncol"},{"key":"610_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(97)08468-7","volume":"351","author":"J Lau","year":"1998","unstructured":"Lau J, Ioannidis JP, Schmid CH. Summing up evidence: oneanswer is not always enough. Lancet. 1998;351:123\u20137.","journal-title":"Lancet."},{"key":"610_CR22","first-page":"381","volume-title":"Update on intravesical agents for non-muscle-invasive bladder cancer. Immunotherapy","author":"SF Shariat","year":"2010","unstructured":"Shariat SF, Chade DC, Karakiewicz PI, Scherr DS, Dalbagni G. Update on intravesical agents for non-muscle-invasive bladder cancer. Immunotherapy, vol. 2; 2010. p. 381\u201392."},{"key":"610_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1464-410X.2011.10880.x","volume":"109","author":"MD Shelley","year":"2012","unstructured":"Shelley MD, Jones G, Cleves A, et al. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. BJU Int. 2012;109:496\u2013505.","journal-title":"BJU Int"},{"key":"610_CR24","doi-asserted-by":"publisher","unstructured":"Peyton CC, Chipollini J, Azizi M, et al. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what. World J Urol. 2018. https:\/\/doi.org\/10.1007\/s00345-018-2591-1.","DOI":"10.1007\/s00345-018-2591-1"},{"key":"610_CR25","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cole R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long term results in 1054 patients. J Clin Oncol. 2001;19:666\u201375.","journal-title":"J Clin Oncol"},{"key":"610_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1586\/14737140.2016.1143777","volume":"16","author":"K Schlack","year":"2016","unstructured":"Schlack K, Boegemann M, Steinestel J, Schrader AJ, Krabbe LM. The safety and efficacy of gemcitabine for the treatment of bladder cancer. Expert Rev Anticancer Ther. 2016;16:255\u201371.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"18","key":"610_CR27","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2018.4657","volume":"319","author":"EM Messing","year":"2018","unstructured":"Messing EM, Tangen CM, Lerner SP, et al. Effect of Intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder Cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA. 2018;319(18):1880\u20138.","journal-title":"JAMA."},{"key":"610_CR28","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","volume":"24","author":"G Dalbagni","year":"2006","unstructured":"Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24:2729\u201334.","journal-title":"J Clin Oncol"},{"key":"610_CR29","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","volume":"66","author":"R Bartoletti","year":"2005","unstructured":"Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology. 2005;66:726\u201331.","journal-title":"Urology."},{"key":"610_CR30","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1586\/14737140.6.8.1273","volume":"6","author":"C Bolenz","year":"2006","unstructured":"Bolenz C, Cao Y, Arancibia MF, et al. Intravesical mitomycin C for superficial transitional cell carcinoma. Expert Anticancer Ther. 2006;6:1273\u201382.","journal-title":"Expert Anticancer Ther"},{"key":"610_CR31","first-page":"CD009294","volume":"1","author":"G Jones","year":"2012","unstructured":"Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2012;1:CD009294 Published 2012 Jan 18.","journal-title":"Cochrane Database Syst Rev"},{"key":"610_CR32","unstructured":"Centers for Medicare & Medicaid Services. 2020 ASP Drug Pricing Files. https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2020-asp-drug-pricing-files. Accessed 5 Jan 2020."}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00610-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-020-00610-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00610-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T23:29:25Z","timestamp":1626132565000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-020-00610-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1186\/s12894-020-00610-9","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"11 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}